First Financial Bank Trust Division trimmed its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 32.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 39,138 shares of the biopharmaceutical company’s stock after selling 18,745 shares during the quarter. First Financial Bank Trust Division’s holdings in Bristol-Myers Squibb were worth $2,398,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Blue Chip Partners Inc. raised its stake in shares of Bristol-Myers Squibb by 0.7% in the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 15 shares during the last quarter. Jackson Grant Investment Advisers Inc. raised its stake in shares of Bristol-Myers Squibb by 0.4% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 15 shares during the last quarter. Chilton Investment Co. LLC raised its stake in shares of Bristol-Myers Squibb by 0.5% in the second quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock worth $294,000 after purchasing an additional 26 shares during the last quarter. Keel Point LLC raised its stake in shares of Bristol-Myers Squibb by 0.6% in the second quarter. Keel Point LLC now owns 6,325 shares of the biopharmaceutical company’s stock worth $352,000 after purchasing an additional 39 shares during the last quarter. Finally, Hudock Capital Group LLC raised its stake in shares of Bristol-Myers Squibb by 0.4% in the second quarter. Hudock Capital Group LLC now owns 11,775 shares of the biopharmaceutical company’s stock worth $656,000 after purchasing an additional 49 shares during the last quarter. 69.70% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts recently commented on BMY shares. Zacks Investment Research cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Citigroup upped their price objective on Bristol-Myers Squibb to $72.00 and gave the company a “buy” rating in a research report on Wednesday, October 18th. Vetr cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price objective for the company. in a research report on Tuesday, January 16th. BMO Capital Markets set a $49.00 price objective on Bristol-Myers Squibb and gave the company a “sell” rating in a research report on Monday, December 11th. Finally, Credit Suisse Group set a $62.00 price objective on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Monday, January 22nd. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the company’s stock. Bristol-Myers Squibb presently has an average rating of “Hold” and an average target price of $65.58.

Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at $62.70 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. The company has a market capitalization of $102,620.00, a PE ratio of 106.27, a price-to-earnings-growth ratio of 1.95 and a beta of 1.08. Bristol-Myers Squibb Co has a 1 year low of $51.52 and a 1 year high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. The business had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. Bristol-Myers Squibb had a return on equity of 33.68% and a net margin of 4.85%. The business’s quarterly revenue was up 3.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.63 earnings per share. sell-side analysts expect that Bristol-Myers Squibb Co will post 3.22 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Friday, January 5th were given a $0.40 dividend. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date was Thursday, January 4th. This represents a $1.60 dividend on an annualized basis and a yield of 2.55%. Bristol-Myers Squibb’s dividend payout ratio is presently 271.19%.

In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares in the company, valued at $37,031,717.01. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the sale, the executive vice president now owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.

TRADEMARK VIOLATION WARNING: “First Financial Bank Trust Division Has $2.40 Million Holdings in Bristol-Myers Squibb Co (BMY)” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://theolympiareport.com/2018/02/11/first-financial-bank-trust-division-has-2-40-million-holdings-in-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.